Transfemoral transcatheter valve-in-valve-in-valve replacement

Stephane Leung Wai Sang, MD, MSc, a Jay Giri, MD, MPH, b and Prashanth Vallabhajosyula, MD, MS a

Video clip is available online.

Transcatheter valve-in-valve (ViV) implantation for degenerated bioprosthetic aortic valves is feasible with acceptable outcomes. 1 The transcatheter valve-in-valve-in-valve operation has not been previously reported.

A 64-year-old man with known severe prosthetic aortic stenosis (AS) was admitted for recurrent decompensated heart failure. His past surgical history included open aortic valve replacement for severe AS in 2006 with a 23-mm Perimount Edwards bioprosthesis, followed by a transcatheter ViV implantation with a 23-mm Sapien XT (Edwards Lifesciences, Irvine, Calif) in 2012 for severe prosthetic AS (peak/mean gradients 121/82.5 mm Hg, and aortic valve area of 0.66 cm²). Present echocardiogram confirmed restenosis (peak/mean gradients, 105/65 mm Hg), with preserved left ventricular function. The patient was deemed to be high risk for open surgery, both in 2012 and currently,

due to advanced biopsy-proven idiopathic liver cirrhosis (Child Turcotte Pugh Class B) and, therefore, was evaluated for transcatheter intervention.

By computed tomographic angiogram, the aortic annular perimeter measured 58.4 mm, with an average diameter of 18.2 mm (Figure 1). These measurements dictated use of a 23-mm Evolut R (Medtronic, Inc, Minneapolis, Minn) transcatheter heart valve (THV). This valve was chosen primarily due to its supra-annular positioning that was postulated to provide a larger effective bioprosthetic area in the current setting, after consideration also was given to a balloon-expandable 20-mm Sapien XT.

The THV was successfully deployed in a position significantly superior to the prior prosthetic valvular complex, relying on the previous stent frames to provide stability for the most proximal portion of the new stent frame (Figure 2, A). Experimental data support that supravalvular implantation of THV relieves stenosis in a small bioprosthesis. Postdeployment aortogram showed no residual paravalvular or valvular leak (Figure 2, B, and Video 1). Immediate postprocedure transesophageal echocardiography revealed a 50% reduction in the aortic mean gradient from 62 mm Hg to 31 mm Hg. Follow-up 30-day transthoracic echocardiography revealed a peak/mean gradient of 31/21 mm Hg.

References